🔗

Mappings

MONDO

MONDO:0010726 Rett syndrome

ORPHA:778 lists MONDO:0010726 as an exact cross-reference.

ICD-10-CM

ICD10CM:F84.2 Rett's syndrome

ORPHA:778 lists ICD-10:F84.2 as an exact cross-reference; this entry records the corresponding ICD-10-CM code.

ICD-11 Foundation

icd11f:201200685 Rett syndrome

ORPHA:778 lists ICD-11:LD90.4 as an exact cross-reference; the ICD-11 Foundation identifier resolves to Rett syndrome.

📘

Definitions

1

Orphanet clinical definition for Rett syndrome

Orphanet defines Rett syndrome as a rare severe X-linked neurodevelopmental disorder with rapid developmental regression in infancy, loss of purposeful hand movements and speech, gait abnormalities, stereotypic hand movements, deceleration of head growth, seizures, breathing abnormalities, and gastrointestinal, scoliosis, and behavioral comorbidities.

CASE_DEFINITION Orphanet disease-level clinical framing for ORPHA:778

Show evidence (1 reference)

ORPHA:778 SUPPORT Other

"A rare severe, X-linked, neurodevelopmental disorder characterized by rapid developmental regression in infancy, partial or complete loss of purposeful hand movements, loss of speech, gait abnormalities, and stereotypic hand movements"

Orphanet's definition supports the core clinical framing and infantile regression pattern for Rett syndrome.

👪

Inheritance

1

X-linked dominant inheritance HP:0001423

Orphanet classifies Rett syndrome as X-linked dominant.

X-linked dominant inheritance

Show evidence (1 reference)

ORPHA:778 SUPPORT Other

"X-linked dominant"

The Orphanet inheritance section directly lists X-linked dominant inheritance for ORPHA:778.

◆

Subtypes

2

Classic Rett Syndrome MONDO:0010726

Typical presentation with regression, hand stereotypies, gait abnormalities, and acquired microcephaly.

Atypical Rett Syndrome MONDO:0017746

Variants including preserved speech, early seizure onset, or congenital forms.

◈

Mechanistic Hypotheses

1

Canonical MECP2 Loss / Transcriptional & Synaptic Dysregulation Model

canonical_mecp2_loss_transcriptional_synaptic_dysregulation_model CANONICAL

Rett syndrome is caused predominantly by de novo loss-of-function variants in MECP2 on Xq28 in heterozygous females (hemizygous males are typically neonatally lethal). MeCP2 is a methyl-CpG- binding nuclear protein that functions as a context-dependent transcriptional regulator (predominantly repressor of long, methylated genes) and a chromatin modifier, with highest expression in postmitotic neurons. MeCP2 loss disrupts the normal repression of long neuronal genes, dysregulates BDNF and other neurotrophin expression, and produces failure of postnatal synaptic and dendritic maturation. The resulting circuit dysfunction — affecting GABAergic interneurons, monoaminergic systems, and excitatory/inhibitory balance — drives the apparent developmental regression, loss of purposeful hand use, stereotypies, autonomic dysfunction, and epilepsy of Rett. Reversibility of the phenotype in conditional Mecp2 reactivation in mice, and gene-replacement (AAV- MECP2) and trofinetide (IGF-1 analogue) clinical-trial data, all corroborate MECP2-loss as the canonical, potentially reversible, pathogenic lesion.

Retained as CANONICAL with major qualifications. The 2026 openscientist hypothesis-search report (kb/hypotheses/Rett_Syndrome/canonical_mecp2_loss_transcriptional_synaptic_dysregulation_model) confirms 21 findings across 136 papers. Three pillars validate the model: (1) MECP2 mutations in >95% of classic RTT, (2) conditional Mecp2 reactivation reverses adult neurological deficits in mice (PMID:24009314), (3) FDA-approved trofinetide (Phase 3 LAVENDER, Cohen's d = 0.43 on communication). Five major qualifications require model expansion: (1) MeCP2 is NOT primarily a gene-specific transcriptional repressor — Skene 2010 showed near-histone-octamer abundance making it a global chromatin architectural protein that dampens transcriptional noise genome-wide; (2) MeCP2 also regulates mRNA splicing, interacts with the Super Elongation Complex, and undergoes activity-dependent post-translational modifications (phosphorylation, SUMOylation) that switch it between repressor and activator functions; (3) Rett is NOT solely a brain disorder — tissue-autonomous pathology occurs in liver, immune cells, skeletal muscle, cardiac tissue, and GI; (4) the phase-separation model for MeCP2 chromatin organization remains contested; (5) prenatal effects on neurogenesis precede the traditionally emphasized postnatal regression. Bidirectional dosage sensitivity (loss → RTT; duplication → MECP2 duplication syndrome) creates a narrow therapeutic window that complicates gene therapy approaches.

Deep research

OpenScientist citations 55 citations 2026-05-23T23:18:26.729699

Show evidence (1 reference)

PMID:10508514 SUPPORT Human Clinical

"we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"

Canonical mechanism reference used as the seed for the hypothesis-search deep-research run.

⚙

Pathophysiology

8

MECP2 Pathogenic Variants

De novo and inherited pathogenic variants in the X-linked MECP2 gene disrupt methyl-CpG-binding protein 2. Reported Rett-causing variant classes include methyl-binding-domain missense substitutions and frameshift or nonsense variants that disrupt the transcription repression domain.

neuron link

MECP2 link

epigenetic regulation of gene expression link ↕ DYSREGULATED

Downstream

Loss of MeCP2 Epigenetic Regulation Pathogenic MECP2 variants disrupt the DNA-binding and transcriptional-regulatory functions of MeCP2.

Variant-Dependent Clinical Severity Different recurrent MECP2 mutations modify the expected severity of motor, hand-use, and language phenotypes.

Show evidence (3 references)

PMID:10508514 SUPPORT Human Clinical

"we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"

Original discovery paper identifies MECP2 pathogenic variants as causative in Rett syndrome.

PMID:10508514 SUPPORT Human Clinical

"In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation"

Establishes the relevant Rett variant classes and the affected MeCP2 protein domains.

ORPHA:778 SUPPORT Other

"MECP2 | methyl-CpG binding protein 2 | hgnc:6990 | Disease-causing germline mutation(s) in"

Orphanet's gene table independently supports MECP2 as a disease-causing germline gene for Rett syndrome.

Loss of MeCP2 Epigenetic Regulation

MeCP2 normally binds methylated CpG dinucleotides and participates in transcriptional repression and activation. Loss or altered dosage of MeCP2 changes neuronal gene-expression programs, providing the proximal molecular bridge from MECP2 mutation to downstream neurodevelopmental defects.

neuron link

MECP2 link

epigenetic regulation of gene expression link ↕ DYSREGULATED regulation of gene expression link ↕ DYSREGULATED

Downstream

Dysregulated Neuronal Gene Expression Loss of MeCP2 regulatory function changes expression of many neuronal genes.

Show evidence (2 references)

PMID:10508514 SUPPORT Human Clinical

"MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A"

Original discovery paper confirms MeCP2 functions as a transcriptional regulator through DNA methylation binding.

PMID:18511691 SUPPORT Model Organism

"These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription."

Mouse hypothalamus data support MeCP2 as a broad transcriptional activator and repressor.

Dysregulated Neuronal Gene Expression

MeCP2 dysfunction induces widespread gene-expression changes in neural tissue. These altered transcriptional programs affect neuronal maturation, synapse organization, dendritic morphology, calcium signaling, and electrophysiological maturation in human Rett cellular models.

neuron link

MECP2 link

regulation of gene expression link ↕ DYSREGULATED

Downstream

Reduced Synapse and Dendritic Spine Density Dysregulated neuronal gene expression affects synapse and dendrite maturation.

Reduced Neuronal Soma Size Dysregulated neuronal maturation contributes to smaller neuronal soma size.

Show evidence (2 references)

PMID:18511691 SUPPORT Model Organism

"MeCP2 dysfunction induced changes in the expression levels of thousands of genes"

MeCP2 loss or overexpression causes broad gene-expression dysregulation in neural tissue.

PMID:21074045 SUPPORT In Vitro

"Our data uncovered early alterations in developing human RTT neurons."

Patient-derived iPSC neurons show early human neuronal defects downstream of MECP2 mutation.

Reduced Synapse and Dendritic Spine Density

Human neurons derived from Rett iPSCs show fewer synapses and reduced spine density, indicating impaired synapse and dendritic maturation in MECP2-mutant neurons.

glutamatergic neuron link neuron link

synapse organization link ↓ DECREASED dendrite morphogenesis link ↓ DECREASED

Downstream

Altered Neuronal Calcium Signaling and Electrophysiology Fewer synapses and dendritic spines reduce mature neuronal connectivity and activity.

Developmental Regression Synaptic and dendritic defects provide a cellular path to loss of acquired language and hand skills.

Intellectual Disability Impaired synaptic maturation disrupts cognitive neurodevelopment.

Autistic Behavior Altered synaptic connectivity contributes to autistic features in Rett syndrome.

Show evidence (1 reference)

PMID:21074045 SUPPORT In Vitro

"Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls."

Patient-derived Rett iPSC neurons directly show reduced synapse number and spine density.

Reduced Neuronal Soma Size

Rett patient-derived neurons are smaller than control neurons, linking MECP2-dependent neuronal maturation defects to reduced brain and head growth.

neuron link

neuron projection morphogenesis link ↓ DECREASED

Downstream

Secondary Microcephaly Reduced neuronal soma size and maturation defects provide a cellular path to postnatal head-growth deceleration.

Show evidence (1 reference)

PMID:21074045 SUPPORT In Vitro

"Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls."

The same patient-derived neuronal model directly documents smaller neuronal soma size.

Altered Neuronal Calcium Signaling and Electrophysiology

MECP2-mutant neurons show altered calcium signaling and electrophysiological defects, indicating impaired activity-dependent network maturation. This network-level dysfunction connects synaptic defects to seizures, motor abnormalities, hand stereotypies, developmental regression, and impaired cognition.

neuron link

chemical synaptic transmission link ↕ DYSREGULATED regulation of synaptic plasticity link ↕ DYSREGULATED

Downstream

Seizures Disrupted neuronal activity and synaptic transmission increase seizure susceptibility.

Gait Abnormalities Network dysfunction affects motor coordination and gait.

Stereotypical Hand Movements Network dysfunction affects purposeful and stereotyped hand motor control.

Developmental Regression Network dysfunction contributes to loss of acquired language and hand skills.

Loss of Spoken Language Network dysfunction contributes to the loss of acquired spoken language.

Sleep Disturbance Neuronal and circadian rhythm dysfunction contributes to sleep problems in Rett syndrome.

Constipation Neuronal and autonomic dysfunction contributes to gastrointestinal dysmotility and constipation.

Brainstem Respiratory Circuit Dysregulation MeCP2-dependent neuronal dysfunction also affects respiratory control circuits.

Show evidence (1 reference)

PMID:21074045 SUPPORT In Vitro

"Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls."

Human Rett iPSC-derived neurons show calcium-signaling and electrophysiological abnormalities.

Brainstem Respiratory Circuit Dysregulation

Breathing disturbances arise from MeCP2-dependent dysfunction in respiratory control networks, including ventrolateral medulla and pontine circuits.

neuron link

chemical synaptic transmission link ↕ DYSREGULATED

brainstem link

Downstream

Breathing Abnormalities Brainstem respiratory circuit dysfunction manifests as hyperventilation, hypoventilation, apnea, and irregular breathing.

Show evidence (1 reference)

PMID:23816600 SUPPORT Model Organism

"Research in mouse models of RTT suggests that different areas in the ventrolateral medulla and pons give rise to different aspects of this breathing disorder."

Mouse model studies connect MeCP2 dysfunction in defined brainstem respiratory circuits to Rett breathing disturbances.

Variant-Dependent Clinical Severity

Recurrent MECP2 variants alter the severity profile of the downstream phenotype. R168X and large deletions are associated with greater severity, while R133C, R294X, and carboxy-terminal truncations are associated with milder motor, hand-use, language, or scoliosis risk profiles in cohort studies.

MECP2 link

Downstream

Gait Abnormalities Mutation group influences walking and ambulation outcomes.

Developmental Regression Mutation group influences retained hand use and language.

Scoliosis Mutation group and motor severity influence scoliosis risk.

Show evidence (3 references)

PMID:18337588 SUPPORT Human Clinical

"Specific mutations in MECP2 confer different severity."

Cohort study establishes variant-specific severity effects.

PMID:18337588 SUPPORT Human Clinical

"Clinical differences are notable in ambulation, hand use, and language (p < 0.004), three cardinal features of Rett syndrome."

Variant-specific severity maps to motor, hand-use, and language features.

PMID:20032810 SUPPORT Human Clinical

"Two common methyl-CpG-binding protein 2 (MECP2) mutations, R294X and R306C, had reduced risk for scoliosis."

Scoliosis cohort study links MECP2 mutation group with scoliosis risk.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Digestive 1

Constipation FREQUENT Constipation (HP:0002019)

RNHS registry analysis reported constipation in 74.5% of females with Rett syndrome.

Show evidence (3 references)

PMID:39511247 SUPPORT Human Clinical

"Affected individuals may present multiple other neurological impairments and comorbidities, such as seizures, breathing irregularities, anxiety and constipation."

Recent disease primer lists constipation among Rett syndrome comorbidities.

PMID:27473171 SUPPORT Human Clinical

"Rett syndrome (RTT), a progressive neurological disorder mainly caused by mutations in MeCP2 gene, is commonly associated with gastrointestinal dysfunctions and constipation, suggesting a link between RTT's gastrointestinal abnormalities and the gut microbiota."

Human cohort microbiome study supports constipation as a common gastrointestinal manifestation.

DOI:10.1186/s11689-024-09557-6 SUPPORT Human Clinical

"A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals."

Identifies the RNHS cohort used to quantify constipation frequency in the full study tables.

Head and Neck 1

Secondary Microcephaly VERY_FREQUENT Secondary microcephaly (HP:0005484)

Head growth deceleration after normal birth head circumference

Show evidence (2 references)

PMID:10508514 PARTIAL Human Clinical

"develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"

Original discovery paper lists microcephaly as a cardinal feature of Rett syndrome.

ORPHA:778 SUPPORT Other

"HP:0000253 | Progressive microcephaly | Very frequent (99-80%)"

Orphanet's curated progressive-microcephaly annotation supports the very-frequent postnatal head-growth deceleration phenotype.

Musculoskeletal 1

Scoliosis FREQUENT Scoliosis (HP:0002650)

Progressive spinal curvature that is common in natural history cohorts and may become severe.

Show evidence (1 reference)

PMID:20032810 SUPPORT Human Clinical

"Scoliosis was noted in 292 (53%); mean age = 15 y with scoliosis and 6 y without."

Natural history cohort documents scoliosis in classic Rett syndrome and provides a cohort frequency.

Context-specific annotations (1)

Orphanet HPO annotation OCCASIONAL

Orphanet classifies scoliosis as occasional in its HPO frequency table.

Show evidence (1 reference)

ORPHA:778 SUPPORT Other

"HP:0002650 | Scoliosis | Occasional (29-5%)"

Orphanet's curated HPO table gives a lower occasional-frequency classification for scoliosis.

Nervous System 9

Global Developmental Delay VERY_FREQUENT Global developmental delay (HP:0001263)

Orphanet classifies global developmental delay as very frequent in Rett syndrome.

Show evidence (1 reference)

ORPHA:778 SUPPORT Other

"HP:0001263 | Global developmental delay | Very frequent (99-80%)"

Orphanet's curated HPO table classifies global developmental delay as very frequent in Rett syndrome.

Developmental Regression VERY_FREQUENT Developmental regression (HP:0002376)

Loss of acquired purposeful hand skills and spoken language between 6-18 months

Show evidence (2 references)

PMID:10508514 PARTIAL Human Clinical

"Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use"

Original discovery paper documents developmental regression with loss of speech and hand skills as hallmark of Rett syndrome.

ORPHA:778 SUPPORT Other

"HP:0002376 | Developmental regression | Very frequent (99-80%)"

Orphanet's curated HPO table independently supports developmental regression as very frequent in Rett syndrome.

Context-specific annotations (1)

Onset: INFANTILE

Show evidence (1 reference)

ORPHA:778 SUPPORT Other

"Age of onset: Infancy"

Orphanet's natural-history section supports infantile onset for the regression-centered disease course.

Stereotypical Hand Movements VERY_FREQUENT Stereotypical hand wringing (HP:0012171)

Characteristic hand wringing, washing, clapping, or mouthing movements

Show evidence (2 references)

PMID:10508514 PARTIAL Human Clinical

"develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"

Original discovery paper identifies stereotypic hand movements as core feature of Rett syndrome.

ORPHA:778 SUPPORT Other

"HP:0012171 | Stereotypical hand wringing | Very frequent (99-80%)"

Orphanet's curated HPO table classifies stereotypical hand wringing as very frequent in Rett syndrome.

Loss of Spoken Language VERY_FREQUENT Absent speech (HP:0001344)

RNHS registry analysis reported loss of language in 95.8% of females with Rett syndrome.

Show evidence (3 references)

PMID:39511247 SUPPORT Human Clinical

"RTT is characterized by developmental regression of spoken language and hand use that, with hand stereotypies and impaired ambulation, constitute the four core diagnostic features."

Recent disease primer identifies spoken-language regression as one of the four core diagnostic features.

DOI:10.1186/s11689-024-09557-6 SUPPORT Human Clinical

"A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals."

Identifies the RNHS cohort used to quantify high-prevalence language loss in the full study tables.

ORPHA:778 SUPPORT Other

"HP:0001344 | Absent speech | Very frequent (99-80%)"

Orphanet's curated HPO table classifies absent speech as very frequent in Rett syndrome.

Gait Abnormalities VERY_FREQUENT Gait disturbance (HP:0001288)

Gait disturbance often includes ataxic gait and may be lost entirely in later stages.

Show evidence (2 references)

PMID:10508514 PARTIAL Human Clinical

"develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"

Original discovery paper lists ataxia as a cardinal feature of Rett syndrome.

ORPHA:778 SUPPORT Other

"HP:0001288 | Gait disturbance | Very frequent (99-80%)"

Orphanet's curated HPO table classifies gait disturbance as very frequent in Rett syndrome.

Seizures FREQUENT Seizure (HP:0001250)

Present in many patients with various seizure types; Orphanet classifies seizure as frequent.

Show evidence (2 references)

PMID:10508514 PARTIAL Human Clinical

"develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"

Original discovery paper lists seizures as a cardinal feature of Rett syndrome.

ORPHA:778 SUPPORT Other

"HP:0001250 | Seizure | Frequent (79-30%)"

Orphanet's curated HPO table classifies seizure as frequent in Rett syndrome.

Intellectual Disability Intellectual disability (HP:0001249)

Show evidence (2 references)

PMID:10508514 SUPPORT Human Clinical

"Rett syndrome (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females"

Discovery paper identifies Rett syndrome as a major cause of intellectual disability in females.

ORPHA:778 SUPPORT Other

"severe intellectual disability"

Orphanet's definition lists severe intellectual disability among commonly associated Rett syndrome features.

Autistic Behavior Autistic behavior (HP:0000729)

Show evidence (1 reference)

PMID:10508514 SUPPORT Human Clinical

"develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"

Original discovery paper lists autism among the core clinical features of classic Rett syndrome.

Sleep Disturbance FREQUENT Sleep disturbance (HP:0002360)

RNHS registry analysis reported sleep disturbances in 75.6% of females with Rett syndrome.

Show evidence (2 references)

PMID:35299616 SUPPORT Human Clinical

"Over 80% of individuals affected by RTT show sleep problems, with a higher prevalence in the first 7 years of life and some degree of variability in correlation to age and genotype."

Review supports sleep problems as a common Rett syndrome feature.

DOI:10.1186/s11689-024-09557-6 SUPPORT Human Clinical

"A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals."

Identifies the RNHS cohort used to quantify sleep disturbance frequency in the full study tables.

Other 2

Breathing Abnormalities VERY_FREQUENT Abnormal pattern of respiration (HP:0002793)

Hyperventilation, breath-holding, air swallowing while awake

Show evidence (2 references)

PMID:23103540 SUPPORT Human Clinical

"hyperventilation and apnea during wakefulness were present in all patients"

Study confirms breathing abnormalities including hyperventilation and apnea are universal in Rett syndrome patients.

ORPHA:778 SUPPORT Other

"HP:0002793 | Abnormal pattern of respiration | Very frequent (99-80%)"

Orphanet's curated HPO table classifies abnormal pattern of respiration as very frequent in Rett syndrome.

Bruxism FREQUENT Bruxism (HP:0003763)

Orphanet classifies bruxism as frequent in Rett syndrome.

Show evidence (1 reference)

ORPHA:778 SUPPORT Other

"HP:0003763 | Bruxism | Frequent (79-30%)"

Orphanet's curated HPO table classifies bruxism as frequent in Rett syndrome.

🧬

Genetic Associations

1

MECP2 (Causative)

X-linked dominant inheritance

Show evidence (4 references)

PMID:10508514 SUPPORT Human Clinical

"we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"

Original discovery paper identified MECP2 mutations as the cause of Rett syndrome.

PMID:18337588 SUPPORT Human Clinical

"Specific mutations in MECP2 confer different severity."

Establishes variable expressivity according to recurrent MECP2 mutation class.

ORPHA:778 SUPPORT Other

"MECP2 | methyl-CpG binding protein 2 | hgnc:6990 | Disease-causing germline mutation(s) in"

Orphanet's gene table supports MECP2 as the disease-causing germline gene for Rett syndrome.

+ 1 more reference

💊

Treatments

6

Trofinetide

Action: Pharmacotherapy NCIT:C15986

Agent: trofinetide ↗

Oral synthetic glycine-proline-glutamate analog supported by a phase 3 randomized trial for improvement in core Rett syndrome symptoms.

Mechanism Target:

MODULATES Reduced Synapse and Dendritic Spine Density — Trofinetide is an IGF-1-related tripeptide analog; IGF1 treatment in Rett patient-derived neurons increased glutamatergic synapse number, linking the drug class to the synaptic node in the pathograph.

Show evidence (2 references)

PMID:37291210 SUPPORT Human Clinical

"Trofinetide is a synthetic analog of glycine-proline-glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome."

Describes trofinetide as an IGF-1-related tripeptide analog and establishes the clinical rationale.

PMID:21074045 PARTIAL In Vitro

"We treated RTT-derived neurons carrying different MeCP2 mutations in culture with IGF1 and observed an increase in glutamatergic synapse number"

Provides human cellular support that IGF1-related pharmacology can modulate the reduced synapse phenotype.

Target Phenotypes: Autistic behavior ↗ Intellectual disability ↗

Show evidence (2 references)

PMID:37291210 SUPPORT Human Clinical

"Significant improvement for trofinetide compared with placebo was observed for the coprimary efficacy endpoints, suggesting that trofinetide provides benefit in treating the core symptoms of Rett syndrome."

Phase 3 randomized trial supports trofinetide benefit for core Rett syndrome symptoms.

clinicaltrials:NCT04181723 SUPPORT Human Clinical

"To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome"

Trial registration documents the randomized oral trofinetide study in females with Rett syndrome.

Seizure Management

Action: Pharmacotherapy NCIT:C15986

Anticonvulsant medications for seizure control.

Show evidence (1 reference)

PMID:23103540 PARTIAL Human Clinical

"Myoclonic seizures aggravated by inappropriate treatment were evident in four patients"

Study documents importance of appropriate seizure management in Rett syndrome patients.

Physical Therapy

Action: physical therapy MAXO:0000011

Maintain mobility, prevent contractures, manage scoliosis.

Occupational Therapy

Action: occupational therapy MAXO:0001351

Adaptive strategies for activities of daily living.

Speech Therapy

Action: speech therapy MAXO:0000930

Augmentative and alternative communication strategies.

Nutritional Support

Action: dietary intervention MAXO:0000088

Address feeding difficulties and maintain adequate nutrition.

🔬

Biochemical Markers

1

MECP2 Protein (Absent or dysfunctional)

Context: Reduced or dysfunctional in affected neural tissues

🔬

Clinical Trials

3

NCT05898620 PHASE_III RECRUITING

Pivotal open-label NGN-401 AAV9 MECP2 gene therapy study in females with typical Rett syndrome.

Target Phenotypes: Developmental regression ↗ Absent speech ↗

Show evidence (1 reference)

clinicaltrials:NCT05898620 SUPPORT Human Clinical

"This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome."

ClinicalTrials.gov record documents the active NGN-401 gene therapy trial for typical Rett syndrome.

NCT06739434 NOT_APPLICABLE ENROLLING_BY_INVITATION

Open-label, dose-escalation GCB-002 intrathecal gene therapy study in female subjects with MECP2 mutation-associated Rett syndrome.

Target Phenotypes: Developmental regression ↗

Show evidence (1 reference)

clinicaltrials:NCT06739434 SUPPORT Human Clinical

"This study explored dose escalation of single-arm, open, single intrathecal injection in female RTT subjects with MECP2 gene mutations."

ClinicalTrials.gov record documents an active GCB-002 intrathecal gene therapy trial in MECP2-related Rett syndrome.

NCT06856759 NOT_APPLICABLE RECRUITING

Dose-exploration study of single intrathecal AAV-MECP2 for safety, tolerability, and preliminary efficacy in Rett syndrome.

Target Phenotypes: Developmental regression ↗

Show evidence (1 reference)

clinicaltrials:NCT06856759 SUPPORT Human Clinical

"The dose exploration study of AAV-MECP2 initiated by our researchers is a multicenter, single arm, single intrathecal injection."

ClinicalTrials.gov record documents a recruiting AAV-MECP2 dose-exploration study for Rett syndrome.

{ }

Source YAML

click to show

name: Rett Syndrome
creation_date: '2026-01-07T17:31:51Z'
updated_date: '2026-04-27T01:15:34Z'
category: Genetic
parents:
- Neurodevelopmental Disorder
- X-linked Dominant Disorder
disease_term:
  preferred_term: Rett syndrome
  term:
    id: MONDO:0010726
    label: Rett syndrome
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:F84.2
      label: Rett's syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet
    mapping_justification: >-
      ORPHA:778 lists ICD-10:F84.2 as an exact cross-reference; this entry
      records the corresponding ICD-10-CM code.
  icd11f_mappings:
  - term:
      id: icd11f:201200685
      label: Rett syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet
    mapping_justification: >-
      ORPHA:778 lists ICD-11:LD90.4 as an exact cross-reference; the ICD-11
      Foundation identifier resolves to Rett syndrome.
  mondo_mappings:
  - term:
      id: MONDO:0010726
      label: Rett syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: Orphanet
    mapping_justification: ORPHA:778 lists MONDO:0010726 as an exact cross-reference.
definitions:
- name: Orphanet clinical definition for Rett syndrome
  definition_type: CASE_DEFINITION
  description: >-
    Orphanet defines Rett syndrome as a rare severe X-linked neurodevelopmental
    disorder with rapid developmental regression in infancy, loss of purposeful
    hand movements and speech, gait abnormalities, stereotypic hand movements,
    deceleration of head growth, seizures, breathing abnormalities, and
    gastrointestinal, scoliosis, and behavioral comorbidities.
  scope: Orphanet disease-level clinical framing for ORPHA:778
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare severe, X-linked, neurodevelopmental disorder characterized by rapid developmental regression in infancy, partial or complete loss of purposeful hand movements, loss of speech, gait abnormalities, and stereotypic hand movements"
    explanation: Orphanet's definition supports the core clinical framing and infantile regression pattern for Rett syndrome.
external_assertions:
- name: Orphanet ORPHA:778 structured disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:778
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=778
  description: >-
    Orphanet's Rett syndrome record supplies structured disease identity,
    epidemiology, natural-history, gene, phenotype, and exact cross-reference
    rows used here as ORPHA:778 evidence.
  notes: >-
    ORPHA:778 lists exact cross-references to ICD-10:F84.2, ICD-11:LD90.4,
    MONDO:0010726, MeSH:D015518, MedDRA:10077709, OMIM:312750, and
    UMLS:C0035372. The current schema has dedicated mapping slots for
    ICD-10-CM, ICD-11 Foundation, and MONDO; the remaining identifiers are
    retained here as external-assertion evidence.
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Rett syndrome (Disease, Disorder)"
    explanation: The structured cache record identifies ORPHA:778 as the Orphanet Rett syndrome disease record.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MeSH:D015518 | Exact"
    explanation: Orphanet lists MeSH:D015518 as an exact cross-reference for Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MedDRA:10077709 | Exact"
    explanation: Orphanet lists MedDRA:10077709 as an exact cross-reference for Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:312750 | Exact"
    explanation: Orphanet lists OMIM:312750 as an exact cross-reference for Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UMLS:C0035372 | Exact"
    explanation: Orphanet lists UMLS:C0035372 as an exact cross-reference for Rett syndrome.
has_subtypes:
- name: Classic Rett Syndrome
  description: Typical presentation with regression, hand stereotypies, gait abnormalities, and acquired microcephaly.
  subtype_term:
    preferred_term: classic Rett syndrome
    term:
      id: MONDO:0010726
      label: Rett syndrome
- name: Atypical Rett Syndrome
  description: Variants including preserved speech, early seizure onset, or congenital forms.
  subtype_term:
    preferred_term: atypical Rett syndrome
    term:
      id: MONDO:0017746
      label: atypical Rett syndrome
inheritance:
- name: X-linked dominant inheritance
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  description: Orphanet classifies Rett syndrome as X-linked dominant.
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "X-linked dominant"
    explanation: The Orphanet inheritance section directly lists X-linked dominant inheritance for ORPHA:778.
prevalence:
- population: Females in the general population
  percentage: 7.1 per 100,000 females
  notes: >-
    Modern pooled estimates place Rett syndrome prevalence at roughly 5 to 10
    cases per 100,000 females.
  evidence:
  - reference: PMID:36642718
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001)."
    explanation: This systematic review and meta-analysis provides the current pooled prevalence estimate for Rett syndrome in females.
  - reference: PMID:36642718
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite greatly variable precision of estimation, all estimates were compatible with a prevalence range of approximately 5 to 10 cases per 100,000 females based on their respective 95% CIs."
    explanation: The same meta-analysis contextualizes the pooled estimate within the broader expected female prevalence range reported across studies.
- population: Worldwide
  percentage: 1-9 per 100,000 point prevalence
  notes: Orphanet classifies worldwide point prevalence as 1-9 per 100,000.
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Point prevalence | ORPHANET"
    explanation: Orphanet's epidemiology table provides a worldwide point-prevalence class for Rett syndrome.
- population: Europe
  percentage: 1-9 per 100,000 prevalence at birth
  notes: Orphanet classifies European prevalence at birth as 1-9 per 100,000.
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Prevalence at birth | PMID:12378695,PMID:21878110"
    explanation: Orphanet's epidemiology table provides a European prevalence-at-birth class for Rett syndrome.
progression:
- phase: Onset
  age_range: Infancy
  notes: Orphanet classifies the age of onset for Rett syndrome as infancy.
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: The Orphanet natural-history section directly supports infantile onset.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_mecp2_loss_transcriptional_synaptic_dysregulation_model
  hypothesis_label: Canonical MECP2 Loss / Transcriptional & Synaptic Dysregulation Model
  status: CANONICAL
  description: >-
    Rett syndrome is caused predominantly by de novo loss-of-function variants in MECP2 on Xq28 in
    heterozygous females (hemizygous males are typically neonatally lethal). MeCP2 is a methyl-CpG-
    binding nuclear protein that functions as a context-dependent transcriptional regulator
    (predominantly repressor of long, methylated genes) and a chromatin modifier, with highest
    expression in postmitotic neurons. MeCP2 loss disrupts the normal repression of long neuronal genes,
    dysregulates BDNF and other neurotrophin expression, and produces failure of postnatal synaptic and
    dendritic maturation. The resulting circuit dysfunction — affecting GABAergic interneurons,
    monoaminergic systems, and excitatory/inhibitory balance — drives the apparent developmental
    regression, loss of purposeful hand use, stereotypies, autonomic dysfunction, and epilepsy of Rett.
    Reversibility of the phenotype in conditional Mecp2 reactivation in mice, and gene-replacement (AAV-
    MECP2) and trofinetide (IGF-1 analogue) clinical-trial data, all corroborate MECP2-loss as the
    canonical, potentially reversible, pathogenic lesion.
  notes: >-
    Retained as CANONICAL with major qualifications.
    The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Rett_Syndrome/canonical_mecp2_loss_transcriptional_synaptic_dysregulation_model)
    confirms 21 findings across 136 papers. Three pillars validate
    the model: (1) MECP2 mutations in >95% of classic RTT,
    (2) conditional Mecp2 reactivation reverses adult neurological
    deficits in mice (PMID:24009314), (3) FDA-approved trofinetide
    (Phase 3 LAVENDER, Cohen's d = 0.43 on communication).
    Five major qualifications require model expansion: (1) MeCP2 is
    NOT primarily a gene-specific transcriptional repressor —
    Skene 2010 showed near-histone-octamer abundance making it a
    global chromatin architectural protein that dampens
    transcriptional noise genome-wide; (2) MeCP2 also regulates
    mRNA splicing, interacts with the Super Elongation Complex,
    and undergoes activity-dependent post-translational
    modifications (phosphorylation, SUMOylation) that switch it
    between repressor and activator functions; (3) Rett is NOT
    solely a brain disorder — tissue-autonomous pathology occurs
    in liver, immune cells, skeletal muscle, cardiac tissue, and
    GI; (4) the phase-separation model for MeCP2 chromatin
    organization remains contested; (5) prenatal effects on
    neurogenesis precede the traditionally emphasized postnatal
    regression. Bidirectional dosage sensitivity (loss → RTT;
    duplication → MECP2 duplication syndrome) creates a narrow
    therapeutic window that complicates gene therapy approaches.
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"
    explanation: >
      Canonical mechanism reference used as the seed for the
      hypothesis-search deep-research run.
pathophysiology:
- name: MECP2 Pathogenic Variants
  description: >
    De novo and inherited pathogenic variants in the X-linked MECP2 gene disrupt
    methyl-CpG-binding protein 2. Reported Rett-causing variant classes include
    methyl-binding-domain missense substitutions and frameshift or nonsense
    variants that disrupt the transcription repression domain.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Loss of MeCP2 Epigenetic Regulation
    description: Pathogenic MECP2 variants disrupt the DNA-binding and transcriptional-regulatory functions of MeCP2.
  - target: Variant-Dependent Clinical Severity
    description: Different recurrent MECP2 mutations modify the expected severity of motor, hand-use, and language phenotypes.
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"
    explanation: Original discovery paper identifies MECP2 pathogenic variants as causative in Rett syndrome.
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation"
    explanation: Establishes the relevant Rett variant classes and the affected MeCP2 protein domains.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MECP2 | methyl-CpG binding protein 2 | hgnc:6990 | Disease-causing germline mutation(s) in"
    explanation: Orphanet's gene table independently supports MECP2 as a disease-causing germline gene for Rett syndrome.
- name: Loss of MeCP2 Epigenetic Regulation
  description: >
    MeCP2 normally binds methylated CpG dinucleotides and participates in
    transcriptional repression and activation. Loss or altered dosage of MeCP2
    changes neuronal gene-expression programs, providing the proximal molecular
    bridge from MECP2 mutation to downstream neurodevelopmental defects.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
    modifier: DYSREGULATED
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Dysregulated Neuronal Gene Expression
    description: Loss of MeCP2 regulatory function changes expression of many neuronal genes.
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A"
    explanation: Original discovery paper confirms MeCP2 functions as a transcriptional regulator through DNA methylation binding.
  - reference: PMID:18511691
    reference_title: "MeCP2, a key contributor to neurological disease, activates and represses transcription."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription."
    explanation: Mouse hypothalamus data support MeCP2 as a broad transcriptional activator and repressor.
- name: Dysregulated Neuronal Gene Expression
  description: >
    MeCP2 dysfunction induces widespread gene-expression changes in neural
    tissue. These altered transcriptional programs affect neuronal maturation,
    synapse organization, dendritic morphology, calcium signaling, and
    electrophysiological maturation in human Rett cellular models.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of gene expression
    term:
      id: GO:0010468
      label: regulation of gene expression
    modifier: DYSREGULATED
  downstream:
  - target: Reduced Synapse and Dendritic Spine Density
    description: Dysregulated neuronal gene expression affects synapse and dendrite maturation.
  - target: Reduced Neuronal Soma Size
    description: Dysregulated neuronal maturation contributes to smaller neuronal soma size.
  evidence:
  - reference: PMID:18511691
    reference_title: "MeCP2, a key contributor to neurological disease, activates and represses transcription."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "MeCP2 dysfunction induced changes in the expression levels of thousands of genes"
    explanation: MeCP2 loss or overexpression causes broad gene-expression dysregulation in neural tissue.
  - reference: PMID:21074045
    reference_title: "A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our data uncovered early alterations in developing human RTT neurons."
    explanation: Patient-derived iPSC neurons show early human neuronal defects downstream of MECP2 mutation.
- name: Reduced Synapse and Dendritic Spine Density
  description: >
    Human neurons derived from Rett iPSCs show fewer synapses and reduced spine
    density, indicating impaired synapse and dendritic maturation in MECP2-mutant
    neurons.
  cell_types:
  - preferred_term: glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
    modifier: DECREASED
  - preferred_term: dendrite morphogenesis
    term:
      id: GO:0048813
      label: dendrite morphogenesis
    modifier: DECREASED
  downstream:
  - target: Altered Neuronal Calcium Signaling and Electrophysiology
    description: Fewer synapses and dendritic spines reduce mature neuronal connectivity and activity.
  - target: Developmental Regression
    description: Synaptic and dendritic defects provide a cellular path to loss of acquired language and hand skills.
  - target: Intellectual Disability
    description: Impaired synaptic maturation disrupts cognitive neurodevelopment.
  - target: Autistic Behavior
    description: Altered synaptic connectivity contributes to autistic features in Rett syndrome.
  evidence:
  - reference: PMID:21074045
    reference_title: "A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls."
    explanation: Patient-derived Rett iPSC neurons directly show reduced synapse number and spine density.
- name: Reduced Neuronal Soma Size
  description: >
    Rett patient-derived neurons are smaller than control neurons, linking
    MECP2-dependent neuronal maturation defects to reduced brain and head growth.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron projection morphogenesis
    term:
      id: GO:0048812
      label: neuron projection morphogenesis
    modifier: DECREASED
  downstream:
  - target: Secondary Microcephaly
    description: Reduced neuronal soma size and maturation defects provide a cellular path to postnatal head-growth deceleration.
  evidence:
  - reference: PMID:21074045
    reference_title: "A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls."
    explanation: The same patient-derived neuronal model directly documents smaller neuronal soma size.
- name: Altered Neuronal Calcium Signaling and Electrophysiology
  description: >
    MECP2-mutant neurons show altered calcium signaling and electrophysiological
    defects, indicating impaired activity-dependent network maturation. This
    network-level dysfunction connects synaptic defects to seizures, motor
    abnormalities, hand stereotypies, developmental regression, and impaired
    cognition.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DYSREGULATED
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
    modifier: DYSREGULATED
  downstream:
  - target: Seizures
    description: Disrupted neuronal activity and synaptic transmission increase seizure susceptibility.
  - target: Gait Abnormalities
    description: Network dysfunction affects motor coordination and gait.
  - target: Stereotypical Hand Movements
    description: Network dysfunction affects purposeful and stereotyped hand motor control.
  - target: Developmental Regression
    description: Network dysfunction contributes to loss of acquired language and hand skills.
  - target: Loss of Spoken Language
    description: Network dysfunction contributes to the loss of acquired spoken language.
  - target: Sleep Disturbance
    description: Neuronal and circadian rhythm dysfunction contributes to sleep problems in Rett syndrome.
  - target: Constipation
    description: Neuronal and autonomic dysfunction contributes to gastrointestinal dysmotility and constipation.
  - target: Brainstem Respiratory Circuit Dysregulation
    description: MeCP2-dependent neuronal dysfunction also affects respiratory control circuits.
  evidence:
  - reference: PMID:21074045
    reference_title: "A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls."
    explanation: Human Rett iPSC-derived neurons show calcium-signaling and electrophysiological abnormalities.
- name: Brainstem Respiratory Circuit Dysregulation
  description: >
    Breathing disturbances arise from MeCP2-dependent dysfunction in respiratory
    control networks, including ventrolateral medulla and pontine circuits.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DYSREGULATED
  downstream:
  - target: Breathing Abnormalities
    description: Brainstem respiratory circuit dysfunction manifests as hyperventilation, hypoventilation, apnea, and irregular breathing.
  evidence:
  - reference: PMID:23816600
    reference_title: "Breathing challenges in Rett syndrome: lessons learned from humans and animal models."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Research in mouse models of RTT suggests that different areas in the ventrolateral medulla and pons give rise to different aspects of this breathing disorder."
    explanation: Mouse model studies connect MeCP2 dysfunction in defined brainstem respiratory circuits to Rett breathing disturbances.
- name: Variant-Dependent Clinical Severity
  description: >
    Recurrent MECP2 variants alter the severity profile of the downstream
    phenotype. R168X and large deletions are associated with greater severity,
    while R133C, R294X, and carboxy-terminal truncations are associated with
    milder motor, hand-use, language, or scoliosis risk profiles in cohort
    studies.
  genes:
  - preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  downstream:
  - target: Gait Abnormalities
    description: Mutation group influences walking and ambulation outcomes.
  - target: Developmental Regression
    description: Mutation group influences retained hand use and language.
  - target: Scoliosis
    description: Mutation group and motor severity influence scoliosis risk.
  evidence:
  - reference: PMID:18337588
    reference_title: "Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Specific mutations in MECP2 confer different severity."
    explanation: Cohort study establishes variant-specific severity effects.
  - reference: PMID:18337588
    reference_title: "Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical differences are notable in ambulation, hand use, and language (p < 0.004), three cardinal features of Rett syndrome."
    explanation: Variant-specific severity maps to motor, hand-use, and language features.
  - reference: PMID:20032810
    reference_title: "Profiling scoliosis in Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two common methyl-CpG-binding protein 2 (MECP2) mutations, R294X and R306C, had reduced risk for scoliosis."
    explanation: Scoliosis cohort study links MECP2 mutation group with scoliosis risk.
phenotypes:
- name: Global Developmental Delay
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Orphanet classifies global developmental delay as very frequent in Rett syndrome.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001263 | Global developmental delay | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies global developmental delay as very frequent in Rett syndrome.
- name: Developmental Regression
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Loss of acquired purposeful hand skills and spoken language between 6-18 months
  phenotype_term:
    preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  phenotype_contexts:
  - onset:
      onset_category: INFANTILE
      notes: Orphanet classifies disease onset as infancy.
    evidence:
    - reference: ORPHA:778
      reference_title: "Rett syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Age of onset: Infancy"
      explanation: Orphanet's natural-history section supports infantile onset for the regression-centered disease course.
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use"
    explanation: Original discovery paper documents developmental regression with loss of speech and hand skills as hallmark of Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002376 | Developmental regression | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table independently supports developmental regression as very frequent in Rett syndrome.
- name: Stereotypical Hand Movements
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Characteristic hand wringing, washing, clapping, or mouthing movements
  phenotype_term:
    preferred_term: Stereotypical Hand Wringing
    term:
      id: HP:0012171
      label: Stereotypical hand wringing
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"
    explanation: Original discovery paper identifies stereotypic hand movements as core feature of Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012171 | Stereotypical hand wringing | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies stereotypical hand wringing as very frequent in Rett syndrome.
- name: Loss of Spoken Language
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: RNHS registry analysis reported loss of language in 95.8% of females with Rett syndrome.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:39511247
    reference_title: "Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RTT is characterized by developmental regression of spoken language and hand use that, with hand stereotypies and impaired ambulation, constitute the four core diagnostic features."
    explanation: Recent disease primer identifies spoken-language regression as one of the four core diagnostic features.
  - reference: DOI:10.1186/s11689-024-09557-6
    reference_title: "Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals."
    explanation: Identifies the RNHS cohort used to quantify high-prevalence language loss in the full study tables.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001344 | Absent speech | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies absent speech as very frequent in Rett syndrome.
- name: Gait Abnormalities
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Gait disturbance often includes ataxic gait and may be lost entirely in later stages.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"
    explanation: Original discovery paper lists ataxia as a cardinal feature of Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies gait disturbance as very frequent in Rett syndrome.
- name: Secondary Microcephaly
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Head growth deceleration after normal birth head circumference
  phenotype_term:
    preferred_term: Secondary Microcephaly
    term:
      id: HP:0005484
      label: Secondary microcephaly
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"
    explanation: Original discovery paper lists microcephaly as a cardinal feature of Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000253 | Progressive microcephaly | Very frequent (99-80%)"
    explanation: Orphanet's curated progressive-microcephaly annotation supports the very-frequent postnatal head-growth deceleration phenotype.
- name: Seizures
  category: Neurological
  frequency: FREQUENT
  notes: Present in many patients with various seizure types; Orphanet classifies seizure as frequent.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"
    explanation: Original discovery paper lists seizures as a cardinal feature of Rett syndrome.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies seizure as frequent in Rett syndrome.
- name: Breathing Abnormalities
  category: Respiratory
  frequency: VERY_FREQUENT
  notes: Hyperventilation, breath-holding, air swallowing while awake
  phenotype_term:
    preferred_term: Abnormal pattern of respiration
    term:
      id: HP:0002793
      label: Abnormal pattern of respiration
  evidence:
  - reference: PMID:23103540
    reference_title: "Epileptic seizures, movement disorders, and breathing disturbances in Rett syndrome: diagnostic relevance of video-polygraphy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hyperventilation and apnea during wakefulness were present in all patients"
    explanation: Study confirms breathing abnormalities including hyperventilation and apnea are universal in Rett syndrome patients.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002793 | Abnormal pattern of respiration | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies abnormal pattern of respiration as very frequent in Rett syndrome.
- name: Scoliosis
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Progressive spinal curvature that is common in natural history cohorts and may become severe.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  phenotype_contexts:
  - frequency: OCCASIONAL
    population: Orphanet HPO annotation
    notes: Orphanet classifies scoliosis as occasional in its HPO frequency table.
    evidence:
    - reference: ORPHA:778
      reference_title: "Rett syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0002650 | Scoliosis | Occasional (29-5%)"
      explanation: Orphanet's curated HPO table gives a lower occasional-frequency classification for scoliosis.
  evidence:
  - reference: PMID:20032810
    reference_title: "Profiling scoliosis in Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scoliosis was noted in 292 (53%); mean age = 15 y with scoliosis and 6 y without."
    explanation: Natural history cohort documents scoliosis in classic Rett syndrome and provides a cohort frequency.
- name: Intellectual Disability
  category: Neurological
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rett syndrome (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females"
    explanation: Discovery paper identifies Rett syndrome as a major cause of intellectual disability in females.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "severe intellectual disability"
    explanation: Orphanet's definition lists severe intellectual disability among commonly associated Rett syndrome features.
- name: Autistic Behavior
  category: Behavioral
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements"
    explanation: Original discovery paper lists autism among the core clinical features of classic Rett syndrome.
- name: Bruxism
  category: Neurological
  frequency: FREQUENT
  notes: Orphanet classifies bruxism as frequent in Rett syndrome.
  phenotype_term:
    preferred_term: Bruxism
    term:
      id: HP:0003763
      label: Bruxism
  evidence:
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003763 | Bruxism | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies bruxism as frequent in Rett syndrome.
- name: Sleep Disturbance
  category: Neurological
  frequency: FREQUENT
  notes: RNHS registry analysis reported sleep disturbances in 75.6% of females with Rett syndrome.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:35299616
    reference_title: "Sleep Disorders in Rett Syndrome and Rett-Related Disorders: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over 80% of individuals affected by RTT show sleep problems, with a higher prevalence in the first 7 years of life and some degree of variability in correlation to age and genotype."
    explanation: Review supports sleep problems as a common Rett syndrome feature.
  - reference: DOI:10.1186/s11689-024-09557-6
    reference_title: "Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals."
    explanation: Identifies the RNHS cohort used to quantify sleep disturbance frequency in the full study tables.
- name: Constipation
  category: Gastrointestinal
  frequency: FREQUENT
  notes: RNHS registry analysis reported constipation in 74.5% of females with Rett syndrome.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:39511247
    reference_title: "Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals may present multiple other neurological impairments and comorbidities, such as seizures, breathing irregularities, anxiety and constipation."
    explanation: Recent disease primer lists constipation among Rett syndrome comorbidities.
  - reference: PMID:27473171
    reference_title: "Altered gut microbiota in Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rett syndrome (RTT), a progressive neurological disorder mainly caused by mutations in MeCP2 gene, is commonly associated with gastrointestinal dysfunctions and constipation, suggesting a link between RTT's gastrointestinal abnormalities and the gut microbiota."
    explanation: Human cohort microbiome study supports constipation as a common gastrointestinal manifestation.
  - reference: DOI:10.1186/s11689-024-09557-6
    reference_title: "Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals."
    explanation: Identifies the RNHS cohort used to quantify constipation frequency in the full study tables.
biochemical:
- name: MECP2 Protein
  presence: Absent or dysfunctional
  context: Reduced or dysfunctional in affected neural tissues
genetic:
- name: MECP2
  association: Causative
  gene_term:
    preferred_term: MECP2
    term:
      id: hgnc:6990
      label: MECP2
  variant_origin: DE_NOVO
  inheritance:
  - name: X-linked dominant inheritance
    inheritance_term:
      preferred_term: X-linked dominant inheritance
      term:
        id: HP:0001423
        label: X-linked dominant inheritance
    expressivity: VARIABLE
    evidence:
    - reference: ORPHA:778
      reference_title: "Rett syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "X-linked dominant"
      explanation: Orphanet's inheritance section independently supports X-linked dominant inheritance for Rett syndrome.
  notes: >
    X-linked dominant MECP2 disorder that almost exclusively affects females;
    most classic cases are de novo. Disease severity varies by recurrent
    mutation class and by X-chromosome inactivation context.
  variants:
  - name: MECP2 methyl-binding-domain missense variants
    clinical_significance: PATHOGENIC
    description: >
      Recurrent missense variants in the methyl-binding domain impair MeCP2 DNA
      binding and show variant-specific severity effects.
    evidence:
    - reference: PMID:10508514
      reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation"
      explanation: Establishes methyl-binding-domain missense variants as Rett-causing MECP2 variants.
    - reference: PMID:18337588
      reference_title: "Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Participants with the R133C mutation are less severely affected than those with R168X or large DNA deletions (p < 0.05)."
      explanation: Shows a recurrent missense variant with relatively milder severity compared with truncating or deletion variants.
  - name: MECP2 truncating and large-deletion variants
    clinical_significance: PATHOGENIC
    description: >
      Nonsense, frameshift, and large-deletion variants can disrupt MeCP2
      transcriptional repression domains and are often associated with more
      severe clinical outcomes.
    evidence:
    - reference: PMID:10508514
      reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a de novo frameshift and a de novo nonsense mutation, both of which disrupt the transcription repression domain (TRD)."
      explanation: Original discovery paper documents truncating variants disrupting the transcription repression domain.
    - reference: PMID:18337588
      reference_title: "Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Likewise, individuals with the R168X mutation are more severely affected than those with R294X and late carboxy-terminal truncating mutations (p < 0.05)."
      explanation: Cohort genotype-phenotype analysis links truncating mutation class with severity differences.
  evidence:
  - reference: PMID:10508514
    reference_title: "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT"
    explanation: Original discovery paper identified MECP2 mutations as the cause of Rett syndrome.
  - reference: PMID:18337588
    reference_title: "Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Specific mutations in MECP2 confer different severity."
    explanation: Establishes variable expressivity according to recurrent MECP2 mutation class.
  - reference: ORPHA:778
    reference_title: "Rett syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MECP2 | methyl-CpG binding protein 2 | hgnc:6990 | Disease-causing germline mutation(s) in"
    explanation: Orphanet's gene table supports MECP2 as the disease-causing germline gene for Rett syndrome.
  - reference: CGGV:assertion_2df006ff-5ab4-4926-9b72-48909b09e608-2018-05-02T132629.570Z
    reference_title: "MECP2 / Rett syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MECP2 | HGNC:6990 | Rett syndrome | MONDO:0010726 | XL | Definitive"
    explanation: ClinGen classifies the MECP2-Rett syndrome gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Trofinetide
  description: >
    Oral synthetic glycine-proline-glutamate analog supported by a phase 3
    randomized trial for improvement in core Rett syndrome symptoms.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: trofinetide
      term:
        id: CHEBI:229599
        label: trofinetide
  target_phenotypes:
  - preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  target_mechanisms:
  - target: Reduced Synapse and Dendritic Spine Density
    treatment_effect: MODULATES
    description: >
      Trofinetide is an IGF-1-related tripeptide analog; IGF1 treatment in
      Rett patient-derived neurons increased glutamatergic synapse number,
      linking the drug class to the synaptic node in the pathograph.
    evidence:
    - reference: PMID:37291210
      reference_title: "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Trofinetide is a synthetic analog of glycine-proline-glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome."
      explanation: Describes trofinetide as an IGF-1-related tripeptide analog and establishes the clinical rationale.
    - reference: PMID:21074045
      reference_title: "A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells."
      supports: PARTIAL
      evidence_source: IN_VITRO
      snippet: "We treated RTT-derived neurons carrying different MeCP2 mutations in culture with IGF1 and observed an increase in glutamatergic synapse number"
      explanation: Provides human cellular support that IGF1-related pharmacology can modulate the reduced synapse phenotype.
  evidence:
  - reference: PMID:37291210
    reference_title: "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant improvement for trofinetide compared with placebo was observed for the coprimary efficacy endpoints, suggesting that trofinetide provides benefit in treating the core symptoms of Rett syndrome."
    explanation: Phase 3 randomized trial supports trofinetide benefit for core Rett syndrome symptoms.
  - reference: clinicaltrials:NCT04181723
    reference_title: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome"
    explanation: Trial registration documents the randomized oral trofinetide study in females with Rett syndrome.
- name: Seizure Management
  description: Anticonvulsant medications for seizure control.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:23103540
    reference_title: "Epileptic seizures, movement disorders, and breathing disturbances in Rett syndrome: diagnostic relevance of video-polygraphy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Myoclonic seizures aggravated by inappropriate treatment were evident in four patients"
    explanation: Study documents importance of appropriate seizure management in Rett syndrome patients.
- name: Physical Therapy
  description: Maintain mobility, prevent contractures, manage scoliosis.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Occupational Therapy
  description: Adaptive strategies for activities of daily living.
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: MAXO:0001351
      label: occupational therapy
- name: Speech Therapy
  description: Augmentative and alternative communication strategies.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
- name: Nutritional Support
  description: Address feeding difficulties and maintain adequate nutrition.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
clinical_trials:
- name: NCT05898620
  phase: PHASE_III
  status: RECRUITING
  description: >
    Pivotal open-label NGN-401 AAV9 MECP2 gene therapy study in females with
    typical Rett syndrome.
  target_phenotypes:
  - preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  - preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: clinicaltrials:NCT05898620
    reference_title: "A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome."
    explanation: ClinicalTrials.gov record documents the active NGN-401 gene therapy trial for typical Rett syndrome.
- name: NCT06739434
  phase: NOT_APPLICABLE
  status: ENROLLING_BY_INVITATION
  description: >
    Open-label, dose-escalation GCB-002 intrathecal gene therapy study in female
    subjects with MECP2 mutation-associated Rett syndrome.
  target_phenotypes:
  - preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: clinicaltrials:NCT06739434
    reference_title: "An Open Label, Single Arm, Dose Escalation Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of GCB-002 in the Treatment of Female Subjects With MECP2 Gene Mutation in Patients With Rett Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study explored dose escalation of single-arm, open, single intrathecal injection in female RTT subjects with MECP2 gene mutations."
    explanation: ClinicalTrials.gov record documents an active GCB-002 intrathecal gene therapy trial in MECP2-related Rett syndrome.
- name: NCT06856759
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >
    Dose-exploration study of single intrathecal AAV-MECP2 for safety,
    tolerability, and preliminary efficacy in Rett syndrome.
  target_phenotypes:
  - preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: clinicaltrials:NCT06856759
    reference_title: "Study on the Safety, Tolerability, and Preliminary Efficacy of Single Intrathecal Injection of AAV-MECP2 in the Treatment of Rett Syndrome"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The dose exploration study of AAV-MECP2 initiated by our researchers is a multicenter, single arm, single intrathecal injection."
    explanation: ClinicalTrials.gov record documents a recruiting AAV-MECP2 dose-exploration study for Rett syndrome.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 33 citations 2026-04-25T22:29:03.465840

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Rett Syndrome
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on Rett Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Rett Syndrome — Comprehensive Disease Characteristics Research Report (Genetic)

Target Disease

Disease name: Rett syndrome (RTT) (gold2024rettsyndrome pages 1-2)
Category: Genetic neurodevelopmental disorder (gold2024rettsyndrome pages 1-2)
MONDO ID: Not retrieved in the available evidence corpus; should be obtained from Mondo Disease Ontology (not available via current tool state).

Executive overview

Rett syndrome is a severe, progressive neurodevelopmental disorder that predominantly affects females and is a common genetic cause of intellectual disability in girls. It is classically characterized by a period of apparently typical early development followed by developmental stagnation/regression with loss of spoken language and purposeful hand skills, emergence of stereotypic hand movements, and gait abnormalities. Most cases are caused by de novo loss-of-function variants in the X-linked gene MECP2 (Xq28). (gold2024rettsyndrome pages 1-2, neul2023trofinetideforthe pages 1-2)

Direct abstract quote (phase 3 trofinetide trial, 2023): “Rett syndrome is a rare, genetic neurodevelopmental disorder.” (neul2023trofinetideforthe pages 1-2)

1. Disease information

1.1 What is the disease?

RTT is a multisystem neurodevelopmental disorder with prominent neurological, autonomic/respiratory, gastrointestinal, orthopedic, and behavioral comorbidities described in modern natural history and review literature. (percy2024rettsyndromethe pages 1-2, gold2024rettsyndrome pages 1-2)

1.2 Key identifiers

A partial set of identifiers is available from the retrieved sources: - OMIM: 312750 (camillo2024profileoftrofinetide pages 1-2) - Causal gene/locus: MECP2, Xq28 (percy2024rettsyndromethe pages 1-2, gold2024rettsyndrome pages 1-2)

Other requested identifiers were not directly retrievable from the current evidence set: - Orphanet ID, ICD-10/ICD-11 code, MeSH descriptor, MONDO ID: not present in retrieved texts; should be pulled from Orphanet/ICD/MeSH/Mondo resources.

1.3 Synonyms / alternative names

RTT; classic (typical) Rett syndrome; atypical Rett syndrome (may2024characterizingthejourney pages 1-2)

1.4 Evidence provenance: individual vs aggregated

Most information in this report is derived from: - Aggregated disease-level resources and synthesis reviews (Nature Reviews Disease Primers 2024; CNS Drugs 2024) (gold2024rettsyndrome pages 1-2, percy2024rettsyndromethe pages 1-2) - Aggregated registry/natural history data (RNHS registry-based real-world evidence study, N=455 females) (may2024characterizingthejourney pages 1-2, may2024characterizingthejourney pages 2-4) - Randomized controlled trial evidence for treatment (phase 3 LAVENDER trial of trofinetide) (neul2023trofinetideforthe pages 2-3, neul2023trofinetideforthe pages 1-2)

A compact identifiers summary table is provided here:

Item	Value	Source publication year	URL	Source row citation
Disease name	Rett syndrome (RTT)	2024	https://doi.org/10.1038/s41572-024-00568-0	(gold2024rettsyndrome pages 1-2)
Synonyms / alternative names	RTT; classic Rett syndrome; atypical Rett syndrome	2024	https://doi.org/10.1186/s11689-024-09557-6	(may2024characterizingthejourney pages 1-2)
OMIM number	OMIM #312750	2024	https://doi.org/10.2147/DDDT.S383133	(camillo2024profileoftrofinetide pages 1-2)
Causal gene and locus	MECP2; Xq28	2024	https://doi.org/10.1007/s40263-024-01106-y	(percy2024rettsyndromethe pages 1-2)
Key diagnostic main criteria (4)	Loss of acquired purposeful hand skills; loss of spoken language; stereotypic hand movements; gait abnormalities	2024	https://doi.org/10.1186/s11689-024-09557-6	(may2024characterizingthejourney pages 1-2)
Incidence	Approximately 1 in 10,000–15,000 live female births	2024	https://doi.org/10.1186/s11689-024-09557-6	(may2024characterizingthejourney pages 1-2)
Prevalence	7.1 per 100,000 females (95% CI 4.8–10.5)	2023	https://doi.org/10.1186/s13643-023-02169-6	(petriti2023globalprevalenceof pages 1-2)

Table: This table summarizes core disease identifiers and nomenclature for Rett syndrome, including OMIM, causal gene locus, defining diagnostic criteria, and headline epidemiology figures. It is useful as a compact, citable reference for a disease knowledge base entry.

2. Etiology

2.1 Disease causal factors

Primary cause: Pathogenic variants in MECP2, encoding methyl-CpG-binding protein 2 (MeCP2), a DNA-binding protein involved in epigenetic regulation of gene expression. (neul2023trofinetideforthe pages 1-2, gold2024rettsyndrome pages 1-2)

Direct abstract quote (trofinetide development review, 2024): “Rett syndrome (RTT) is rare neurodevelopmental disorder caused by mutations in the MECP2 gene that encodes methyl-CpG-binding protein 2 (MeCP2), a DNA-binding protein with roles in epigenetic regulation of gene expression.” (kennedy2024developmentoftrofinetide pages 1-2)

2.2 Risk factors

Sex: Predominantly affects females; epidemiology commonly framed in females, and incidence estimates are reported for live female births. (neul2023trofinetideforthe pages 1-2, may2024characterizingthejourney pages 1-2)
Genetic: Most classic RTT is caused by spontaneous/de novo MECP2 mutation on the X chromosome; real-world review notes “In 90–95% of classic RTT, a spontaneous MECP2 mutation on the X chromosome is causal.” (may2024characterizingthejourney pages 1-2)

2.3 Protective factors

No protective genetic variants or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

No gene–environment interaction evidence was identified in the retrieved evidence set.

2.5 Genetic architecture details (hotspots)

A 2024 disease primer reports that most cases are associated with de novo loss-of-function variants in MECP2, including >300 LOF variants, with eight hotspot pathogenic variants comprising >60% of documented cases; hotspots often reflect C-to-T transitions at methylated CpG sites. (gold2024rettsyndrome pages 1-2)

Ontology suggestions (etiology): - MONDO: Rett syndrome (to be filled) - Gene: MECP2 (HGNC symbol: MECP2; not retrieved here)

3. Phenotypes

3.1 Core phenotype set and natural history (symptoms/signs)

The classic developmental trajectory includes: - Apparently typical early development for ~6 months - Failure to meet milestones by 6–18 months - Regression typically at ~12–30 months with loss of hand skills and spoken language and emergence of stereotypic hand movements and gait dysfunction - Relative stabilization from ~5 years onward, with possible later loss of ambulation (neul2023trofinetideforthe pages 1-2)

3.2 Phenotype frequencies (from RNHS real-world cohort)

In the US RNHS registry cohort (N=455 females; 90.5% classic), high-prevalence clinical features included: - Loss of language: 95.8% - Hand stereotypies: 92.3% - Respiratory dysfunction: 75.8% - Sleep disturbances: 75.6% - Constipation: 74.5% (may2024characterizingthejourney pages 2-4)

Classic RTT had higher prevalence than atypical RTT for several features (e.g., loss of language 99.5% vs 60.5%; hand stereotypies 94.4% vs 72.1%; respiratory dysfunction 79.1% vs 44.2%). (may2024characterizingthejourney pages 2-4)

3.3 Quality of life impact

Registry and review evidence indicates substantial burden and reliance on supportive therapies and healthcare encounters, consistent with significant functional impairment affecting communication, mobility, and daily living. (may2024characterizingthejourney pages 1-2, may2024characterizingthejourney pages 9-10)

3.4 Suggested HPO terms (examples)

(These are ontology suggestions; exact term IDs should be verified in HPO.) - Loss of purposeful hand skills → Loss of hand skills / Apraxia (HPO suggestion) - Loss of spoken language → Absent speech / Loss of speech (HPO suggestion) - Hand stereotypies → Stereotypy / Hand wringing (HPO suggestion) - Gait abnormalities → Abnormal gait (HPO suggestion) - Breathing abnormalities/respiratory dysfunction → Abnormal breathing pattern (HPO suggestion) - Constipation → Constipation (HPO suggestion) - Sleep disturbance → Sleep disturbance (HPO suggestion)

4. Genetic / molecular information

4.1 Causal genes

MECP2 is the major causal gene for RTT. (gold2024rettsyndrome pages 1-2, neul2023trofinetideforthe pages 1-2)

4.2 Inheritance

RTT is typically discussed as an X-linked disorder with predominantly de novo variants in affected females; incidence is often cited as ~1 in 10,000–15,000 live female births. (neul2023trofinetideforthe pages 1-2, may2024characterizingthejourney pages 1-2)

4.3 Pathogenic variants (high-level)

The 2024 primer describes extensive allelic heterogeneity with >300 LOF variants and concentration into hotspot variants (eight hotspots comprising >60% of cases). (gold2024rettsyndrome pages 1-2)

4.4 Modifier genes / epigenetics

A 2024 study in a clinical care setting evaluated common MTHFR genotypes as potential associative modifiers of clinical severity (not a causal factor). (may2024characterizingthejourney pages 2-4)

Epigenetic mechanism is central because MeCP2 binds methylated DNA and links to histone deacetylation, functioning in transcriptional regulation; functional loss results in broad transcriptional dysregulation. (gold2024rettsyndrome pages 1-2, kennedy2024developmentoftrofinetide pages 1-2)

Ontology suggestions: - GO (molecular function/process examples): DNA-binding; regulation of transcription; chromatin organization (suggestions grounded conceptually in MeCP2 biology; exact GO IDs not retrieved here). (gold2024rettsyndrome pages 1-2)

5. Environmental information

No specific environmental/lifestyle/infectious causal contributors were identified in the retrieved evidence set. RTT is primarily genetic, and available sources emphasize genetic causation. (gold2024rettsyndrome pages 1-2, kennedy2024developmentoftrofinetide pages 1-2)

6. Mechanism / pathophysiology

6.1 Current understanding (key concepts)

MeCP2 is highly expressed in brain and is described as a key regulator linking methylated DNA to chromatin/histone state; MeCP2 deficiency is associated with reduced brain size, smaller neurons, and alterations across neurotransmitter systems. (gold2024rettsyndrome pages 1-2)

A mechanistic chain consistent with the retrieved sources: 1) De novo MECP2 loss-of-function → 2) Disrupted epigenetic/transcriptional regulation (MeCP2 DNA binding; chromatin linking) → 3) Abnormal neuronal maturation and plasticity → 4) Circuit-level dysfunction and multisystem manifestations (communication/motor regression; breathing abnormalities; GI dysfunction; seizures). (kennedy2024developmentoftrofinetide pages 1-2, neul2023trofinetideforthe pages 1-2, percy2024rettsyndromethe pages 1-2)

6.2 Recent developments (2023–2024): single-cell transcriptomics of progression

Sharifi et al. (2024) used longitudinal cortical snRNA-seq in a construct-relevant Mecp2e1 mutant mouse model, analyzing 93,798 nuclei across presymptomatic, onset, and late stages. They report strong sex- and stage-dependent transcriptional dysregulation, with ~6× more differentially expressed genes (DEGs) in mutant females than males, and that female DEGs emerged prior to symptoms and were enriched for homeostatic pathways. They highlight prominent non-cell-autonomous effects across progression, consistent with mosaic X-inactivation biology. (sharifi2024sexspecificsinglecelllevel pages 1-2, sharifi2024sexspecificsinglecelllevel pages 3-4)

6.3 Suggested GO and CL terms (examples)

GO Biological Process (suggested): regulation of transcription; synaptic signaling; neuronal development; homeostatic process (supported conceptually by transcriptomic enrichment descriptions). (sharifi2024sexspecificsinglecelllevel pages 1-2)
CL Cell types (suggested): excitatory cortical neurons (layer-specific), inhibitory interneuron subtypes (e.g., Pvalb, Vip, Sst), oligodendrocytes (all explicitly analyzed in the study). (sharifi2024sexspecificsinglecelllevel pages 3-4, sharifi2024sexspecificsinglecelllevel pages 5-6)

7. Anatomical structures affected

7.1 Organ/system level

Central nervous system involvement is primary, but RTT is described as multisystem with comorbidities involving breathing/respiratory control, gastrointestinal dysfunction, and orthopedic issues (e.g., scoliosis). (percy2024rettsyndromethe pages 1-2, neul2023trofinetideforthe pages 1-2)

7.2 Tissue/cell level

Single-cell studies highlight diverse cortical neuronal and non-neuronal cell types impacted over disease progression, supporting cell-type-specific and non-cell-autonomous mechanisms. (sharifi2024sexspecificsinglecelllevel pages 1-2)

UBERON term suggestions: - Cerebral cortex (UBERON suggestion)

8. Temporal development

RTT classically shows regression after early development, often described as: - Early stagnation around 6–18 months and regression around toddler years, with subsequent stabilization, consistent with both clinical trial background and review staging descriptions. (neul2023trofinetideforthe pages 1-2, camillo2024profileoftrofinetide pages 1-2)

In the RNHS cohort, mean age of motor/communication regression was 2.3 (0.8) years. (may2024characterizingthejourney pages 2-4)

9. Inheritance and population

9.1 Epidemiology

Incidence: commonly cited as ~1 in 10,000–15,000 live female births. (neul2023trofinetideforthe pages 1-2, may2024characterizingthejourney pages 1-2)
Global prevalence (meta-analysis): pooled prevalence 7.1 per 100,000 females (95% CI 4.8–10.5) based on 10 studies totaling 9.57 million women and 673 RTT cases. (petriti2023globalprevalenceof pages 1-2)

Petriti et al. additionally summarize that estimates are broadly compatible with a prevalence range of ~5–10 per 100,000 females. (petriti2023globalprevalenceof pages 1-2)

9.2 Survival / prognosis (headline)

Registry-based and review-level evidence indicates survival into adulthood is common, with a cited estimate that survival is >70% at 45 years. (may2024characterizingthejourney pages 1-2)

10. Diagnostics

10.1 Clinical criteria

Classic RTT diagnosis requires four main criteria: - Loss of acquired purposeful hand skills - Loss of spoken language - Stereotypic hand movements - Gait abnormalities (may2024characterizingthejourney pages 1-2)

Atypical RTT requires ≥2 main criteria plus ≥5 of 11 supportive criteria (supportive criteria list not retrieved in current evidence). (may2024characterizingthejourney pages 1-2)

10.2 Genetic testing

Genetic confirmation frequently involves identifying a pathogenic MECP2 variant; the RNHS cohort reports MECP2-positive status in 98.2% (cohort with high classic RTT proportion). (may2024characterizingthejourney pages 2-4)

10.3 Biomarkers / imaging / electrophysiology

Specific validated biomarkers or imaging signatures were not extracted from the currently retrieved texts; the RNHS and trial literature emphasize clinical scales and caregiver/clinician-reported outcomes. (neul2023trofinetideforthe pages 2-3, may2024characterizingthejourney pages 1-2)

11. Outcome / prognosis

In the RNHS real-world evidence study, pediatric individuals showed increasing trends in clinical severity and motor-behavioral dysfunction over follow-up: - CSS change/year in pediatrics: 0.24 (95% CI 0.03–0.44) - MBA change/year in pediatrics: 1.12 (95% CI 0.63–1.60) (may2024characterizingthejourney pages 1-2)

Healthcare utilization burden was high: 44.6% had a hospital or emergency room visit during median 4-year follow-up. (may2024characterizingthejourney pages 1-2)

12. Treatment

12.1 Approved pharmacotherapy: trofinetide (2023)

Trofinetide is the first FDA-approved therapy for RTT for patients aged ≥2 years, with approval noted as March 2023. (kennedy2024developmentoftrofinetide pages 1-2)

Direct abstract quote (trofinetide development review, 2024): “Trofinetide, a synthetic analog of glycine-proline-glutamate, was approved by the US Food and Drug Administration for the treatment of RTT in adult and pediatric patients aged 2 years and older.” (kennedy2024developmentoftrofinetide pages 1-2)

Phase 3 efficacy and safety (LAVENDER; NCT04181723): - RSBQ LSM change: −4.9 vs −1.7 (P=0.0175; d=0.37) - CGI-I: 3.5 vs 3.8 (P=0.0030; d=0.47) - Key secondary CSBS-DP-IT Social Composite: −0.1 vs −1.1 (P=0.0064; d=0.43) - Diarrhea: 80.6% vs 19.1%; vomiting: 26.9% vs 9.6% (neul2023trofinetideforthe pages 1-2, neul2023trofinetideforthe pages 5-6)

MAXO suggestions: - Pharmacotherapy (trofinetide) (MAXO suggestion) - Symptom management (MAXO suggestion)

12.2 Supportive and rehabilitative care (real-world implementation)

In the RNHS cohort, supportive therapy use was high, especially in pediatrics: - Physical therapy 77.8% overall (87.3% pediatric vs 40.2% adult) - Speech-language therapy 74.1% overall (86.8% pediatric vs 23.9% adult) - Occupational therapy 70.5% overall (82.1% pediatric vs 25.0% adult) (may2024characterizingthejourney pages 4-5)

MAXO suggestions: - Physical therapy; occupational therapy; speech therapy (MAXO suggestions)

12.3 Advanced therapeutics (gene therapy) — clinical trials

Current ClinicalTrials.gov entries in the retrieved corpus include: - NGN-401 (AAV9 MECP2 gene replacement; NCT05898620): Phase 3 listed; recruiting; single ICV injection; 52-week responder endpoints include CGI-I and blinded video milestone attainment. (NCT05898620 chunk 1) - GCB-002 (scAAV9 full-length MECP2; NCT06739434): enrolling by invitation; open-label dose escalation; intrathecal injection; primary outcome safety through 52 weeks; exploratory CGI-I/PGI-I/RSBQ at 52 weeks. (NCT06739434 chunk 1) - AAV-MECP2 (NCT06856759): recruiting; single intrathecal injection; sequential dose escalation in ages 4–10; primary focus on safety/tolerability with DLT assessment. (NCT06856759 chunk 1)

A structured therapies/trials table is provided:

Intervention / modality	Mechanism or purpose	Regulatory / phase / status	Population / age	Delivery route	Key efficacy / implementation findings	Key adverse events / safety notes	Trial ID	Publication date	URL	Evidence
Trofinetide	Synthetic analog of glycine-proline-glutamate (GPE), an IGF-1–related tripeptide analog developed to improve core RTT symptoms and neuronal function	FDA approved, March 2023; phase 3 LAVENDER completed	Females with RTT; LAVENDER enrolled ages 5–20 years	Oral, twice daily	LAVENDER: RSBQ LSM change -4.9 vs -1.7 (P=0.0175; d=0.37); CGI-I 3.5 vs 3.8 (P=0.0030; d=0.47); CSBS-DP-IT Social Composite -0.1 vs -1.1 (P=0.0064; d=0.43); CGI-I responder rate 37.7% vs 15.2%	Diarrhea 80.6% vs 19.1%; vomiting 26.9% vs 9.6%; TEAEs leading to withdrawal 17.2% vs 2.1%; most GI events mild-moderate	NCT04181723	2023-06; 2024-01	https://doi.org/10.1038/s41591-023-02398-1 ; https://doi.org/10.3389/fphar.2023.1341746	(neul2023trofinetideforthe pages 2-3, neul2023trofinetideforthe pages 1-2, neul2023trofinetideforthe pages 5-6, kennedy2024developmentoftrofinetide pages 1-2)
Supportive therapies (real-world RNHS)	Multidisciplinary rehabilitation and supportive management to preserve mobility, communication, and function	Real-world implementation in RNHS registry cohort	Females with RTT; cohort N=455, pediatric and adult subgroups	Outpatient / community / rehabilitative services	Physical therapy 77.8%, speech-language therapy 74.1%, occupational therapy 70.5% overall; pediatric use exceeded adult use: PT 87.3% vs 40.2%, SLT 86.8% vs 23.9%, OT 82.1% vs 25.0%; nearly half (44.6%) had hospital/ER visit over median 4-year follow-up	Not an interventional treatment study; reflects care burden and utilization rather than treatment-emergent AEs	Not applicable	2024-07	https://doi.org/10.1186/s11689-024-09557-6	(may2024characterizingthejourney pages 1-2, may2024characterizingthejourney pages 2-4, may2024characterizingthejourney pages 4-5)
NGN-401 gene therapy	Regulated AAV9 gene replacement carrying full-length human MECP2 with transgene regulation technology to avoid overexpression	Interventional; listed as phase 3 pivotal, open-label, single-arm; RECRUITING	Females with typical RTT caused by MECP2 mutations; pediatric and adolescent/adult cohorts	Single intracerebroventricular (ICV) injection under general anesthesia	Primary efficacy framework includes 52-week responder definition using CGI-I plus attainment of developmental milestones from blinded video assessment; followed for 3 years with planned long-term follow-up	Dose regulation emphasized because MECP2 is dosage-sensitive; one higher-dose pediatric cohort discontinued per registry record	NCT05898620	2023	https://clinicaltrials.gov/study/NCT05898620	(NCT05898620 chunk 1, NCT05898620 chunk 2)
GCB-002 gene therapy	Self-complementary AAV9 carrying full-length human MECP2 transgene product	Interventional; phase NA; ENROLLING_BY_INVITATION	Female children aged 2–10 years with pathogenic MECP2 mutations	Single intrathecal injection; open-label dose-escalation	Primary outcomes focus on drug-related adverse events through 52 weeks; exploratory efficacy includes CGI-I, PGI-I, and RSBQ at 52 weeks	Sentinel dosing, 30-day safety observation, 3+3 escalation/DLT rules; excludes anti-AAV9 neutralizing antibody titer >1:200	NCT06739434	2024	https://clinicaltrials.gov/study/NCT06739434	(NCT06739434 chunk 1)
AAV-MECP2 gene therapy	AAV-MECP2 gene replacement intended to restore MeCP2 expression	Interventional; early-phase dose exploration; RECRUITING	Children aged 4–10 years; planned n=8	Single intrathecal injection	Primary outcomes emphasize safety/tolerability with DLT assessment within 30 days; sequential dose escalation across two dose levels	DMC oversight; protocol cites preclinical survival benefit in knockout mice and monkey safety testing; broader field notes need for careful dose control	NCT06856759	2025	https://clinicaltrials.gov/study/NCT06856759	(NCT06856759 chunk 1)

Table: This table summarizes approved treatment, real-world supportive care use, and active gene therapy programs for Rett syndrome. It highlights efficacy, safety, implementation patterns, and current trial designs to support a knowledge-base or therapeutic landscape overview.

12.4 Expert opinions / analysis (authoritative sources)

The 2024 treatment-strategy review emphasizes that the NIH-funded Natural History Study enabled development of outcome measures, biomarkers/endpoints, and genotype–phenotype correlations, and frames current progress as moving from largely ineffective early trials to a landscape including FDA-approved trofinetide and multiple gene-based approaches (gene replacement, RNA editing, X-chromosome reactivation). (percy2024rettsyndromethe pages 1-2)

13. Prevention

Primary prevention is not generally feasible because most RTT cases arise from de novo pathogenic variants. Prevention strategies therefore primarily involve genetic counseling and reproductive options (not directly retrieved in the current evidence set). Evidence-based counseling details were not extracted from the current corpus.

14. Other species / natural disease

No naturally occurring RTT-equivalent disease in non-human species was identified in the retrieved evidence set.

15. Model organisms

15.1 Mouse models and single-cell progression studies (recent)

A Mecp2e1 mutant mouse model was used in 2024 to perform longitudinal single-nucleus transcriptomics of disease progression (93,798 nuclei), enabling cell-type specific analysis and investigation of mosaicism/non-cell-autonomous effects. (sharifi2024sexspecificsinglecelllevel pages 1-2)

Key statistics (quick list)

Incidence: ~1 in 10,000–15,000 live female births (neul2023trofinetideforthe pages 1-2)
Global prevalence meta-analysis: 7.1 per 100,000 females (95% CI 4.8–10.5), based on 9.57 million women and 673 cases (petriti2023globalprevalenceof pages 1-2)
RNHS real-world cohort (US): N=455 females; 90.5% classic; 44.6% hospital/ER visit over median 4-year follow-up (may2024characterizingthejourney pages 1-2)
Common RNHS phenotype prevalences: loss of language 95.8%, hand stereotypies 92.3%, respiratory dysfunction 75.8%, constipation 74.5% (may2024characterizingthejourney pages 2-4)
Trofinetide LAVENDER trial: diarrhea 80.6% vs 19.1%; RSBQ and CGI-I statistically significant improvements vs placebo at 12 weeks (neul2023trofinetideforthe pages 1-2, neul2023trofinetideforthe pages 5-6)

Notes on evidence gaps and curation needs

PMIDs: The retrieved texts did not include PubMed IDs in the excerpts available; therefore, PMID-preferred citations could not be supplied without additional PubMed/OMIM/Orphanet lookups.
Ontology IDs (MONDO, HPO IDs, GO IDs, UBERON IDs, MAXO IDs): Suggested terms are provided, but the specific IDs should be confirmed against the respective ontology databases.
ICD/MeSH/Orphanet identifiers: Not available in the current retrieved evidence and should be fetched from those databases directly.

References

(gold2024rettsyndrome pages 1-2): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nature Reviews Disease Primers, Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 60 citations.
(neul2023trofinetideforthe pages 1-2): Jeffrey L. Neul, Alan K. Percy, Timothy A. Benke, Elizabeth M. Berry-Kravis, Daniel G. Glaze, Eric D. Marsh, Tim Lin, Serge Stankovic, Kathie M. Bishop, and James M. Youakim. Trofinetide for the treatment of rett syndrome: a randomized phase 3 study. Nature Medicine, 29:1468-1475, Jun 2023. URL: https://doi.org/10.1038/s41591-023-02398-1, doi:10.1038/s41591-023-02398-1. This article has 241 citations and is from a highest quality peer-reviewed journal.
(percy2024rettsyndromethe pages 1-2): Alan K. Percy, Amitha Ananth, and Jeffrey L. Neul. Rett syndrome: the emerging landscape of treatment strategies. CNS Drugs, 38:851-867, Sep 2024. URL: https://doi.org/10.1007/s40263-024-01106-y, doi:10.1007/s40263-024-01106-y. This article has 34 citations and is from a peer-reviewed journal.
(camillo2024profileoftrofinetide pages 1-2): Laura Camillo, Marco Pozzi, Pia Bernardo, Simone Pisano, and Maria Nobile. Profile of trofinetide in the treatment of rett syndrome: design, development and potential place in therapy. Drug Design, Development and Therapy, 18:5023-5040, Nov 2024. URL: https://doi.org/10.2147/dddt.s383133, doi:10.2147/dddt.s383133. This article has 12 citations.
(may2024characterizingthejourney pages 1-2): Damian May, Kalé Kponee-Shovein, Jeffrey L. Neul, Alan K. Percy, Malena Mahendran, Nathaniel Downes, Grace Chen, Talissa Watson, Dominique C. Pichard, Melissa Kennedy, and Patrick Lefebvre. Characterizing the journey of rett syndrome among females in the united states: a real-world evidence study using the rett syndrome natural history study database. Journal of Neurodevelopmental Disorders, Jul 2024. URL: https://doi.org/10.1186/s11689-024-09557-6, doi:10.1186/s11689-024-09557-6. This article has 8 citations and is from a peer-reviewed journal.
(may2024characterizingthejourney pages 2-4): Damian May, Kalé Kponee-Shovein, Jeffrey L. Neul, Alan K. Percy, Malena Mahendran, Nathaniel Downes, Grace Chen, Talissa Watson, Dominique C. Pichard, Melissa Kennedy, and Patrick Lefebvre. Characterizing the journey of rett syndrome among females in the united states: a real-world evidence study using the rett syndrome natural history study database. Journal of Neurodevelopmental Disorders, Jul 2024. URL: https://doi.org/10.1186/s11689-024-09557-6, doi:10.1186/s11689-024-09557-6. This article has 8 citations and is from a peer-reviewed journal.
(neul2023trofinetideforthe pages 2-3): Jeffrey L. Neul, Alan K. Percy, Timothy A. Benke, Elizabeth M. Berry-Kravis, Daniel G. Glaze, Eric D. Marsh, Tim Lin, Serge Stankovic, Kathie M. Bishop, and James M. Youakim. Trofinetide for the treatment of rett syndrome: a randomized phase 3 study. Nature Medicine, 29:1468-1475, Jun 2023. URL: https://doi.org/10.1038/s41591-023-02398-1, doi:10.1038/s41591-023-02398-1. This article has 241 citations and is from a highest quality peer-reviewed journal.
(petriti2023globalprevalenceof pages 1-2): Uarda Petriti, Daniel C. Dudman, Emil Scosyrev, and Sandra Lopez-Leon. Global prevalence of rett syndrome: systematic review and meta-analysis. Systematic Reviews, Jan 2023. URL: https://doi.org/10.1186/s13643-023-02169-6, doi:10.1186/s13643-023-02169-6. This article has 120 citations and is from a peer-reviewed journal.
(kennedy2024developmentoftrofinetide pages 1-2): Melissa Kennedy, Larry Glass, Daniel G. Glaze, Steve Kaminsky, Alan K. Percy, Jeffrey L. Neul, Nancy E. Jones, Daniela Tropea, Joseph P. Horrigan, Paige Nues, Kathie M. Bishop, and James M. Youakim. Development of trofinetide for the treatment of rett syndrome: from bench to bedside. Frontiers in Pharmacology, Jan 2024. URL: https://doi.org/10.3389/fphar.2023.1341746, doi:10.3389/fphar.2023.1341746. This article has 16 citations.
(may2024characterizingthejourney pages 9-10): Damian May, Kalé Kponee-Shovein, Jeffrey L. Neul, Alan K. Percy, Malena Mahendran, Nathaniel Downes, Grace Chen, Talissa Watson, Dominique C. Pichard, Melissa Kennedy, and Patrick Lefebvre. Characterizing the journey of rett syndrome among females in the united states: a real-world evidence study using the rett syndrome natural history study database. Journal of Neurodevelopmental Disorders, Jul 2024. URL: https://doi.org/10.1186/s11689-024-09557-6, doi:10.1186/s11689-024-09557-6. This article has 8 citations and is from a peer-reviewed journal.
(sharifi2024sexspecificsinglecelllevel pages 1-2): Osman Sharifi, Viktoria Haghani, Kari E. Neier, Keith J. Fraga, Ian Korf, Sophia M. Hakam, Gerald Quon, Nelson Johansen, Dag H. Yasui, and Janine M. LaSalle. Sex-specific single cell-level transcriptomic signatures of rett syndrome disease progression. Communications Biology, Oct 2024. URL: https://doi.org/10.1038/s42003-024-06990-0, doi:10.1038/s42003-024-06990-0. This article has 15 citations and is from a peer-reviewed journal.
(sharifi2024sexspecificsinglecelllevel pages 3-4): Osman Sharifi, Viktoria Haghani, Kari E. Neier, Keith J. Fraga, Ian Korf, Sophia M. Hakam, Gerald Quon, Nelson Johansen, Dag H. Yasui, and Janine M. LaSalle. Sex-specific single cell-level transcriptomic signatures of rett syndrome disease progression. Communications Biology, Oct 2024. URL: https://doi.org/10.1038/s42003-024-06990-0, doi:10.1038/s42003-024-06990-0. This article has 15 citations and is from a peer-reviewed journal.
(sharifi2024sexspecificsinglecelllevel pages 5-6): Osman Sharifi, Viktoria Haghani, Kari E. Neier, Keith J. Fraga, Ian Korf, Sophia M. Hakam, Gerald Quon, Nelson Johansen, Dag H. Yasui, and Janine M. LaSalle. Sex-specific single cell-level transcriptomic signatures of rett syndrome disease progression. Communications Biology, Oct 2024. URL: https://doi.org/10.1038/s42003-024-06990-0, doi:10.1038/s42003-024-06990-0. This article has 15 citations and is from a peer-reviewed journal.
(neul2023trofinetideforthe pages 5-6): Jeffrey L. Neul, Alan K. Percy, Timothy A. Benke, Elizabeth M. Berry-Kravis, Daniel G. Glaze, Eric D. Marsh, Tim Lin, Serge Stankovic, Kathie M. Bishop, and James M. Youakim. Trofinetide for the treatment of rett syndrome: a randomized phase 3 study. Nature Medicine, 29:1468-1475, Jun 2023. URL: https://doi.org/10.1038/s41591-023-02398-1, doi:10.1038/s41591-023-02398-1. This article has 241 citations and is from a highest quality peer-reviewed journal.
(may2024characterizingthejourney pages 4-5): Damian May, Kalé Kponee-Shovein, Jeffrey L. Neul, Alan K. Percy, Malena Mahendran, Nathaniel Downes, Grace Chen, Talissa Watson, Dominique C. Pichard, Melissa Kennedy, and Patrick Lefebvre. Characterizing the journey of rett syndrome among females in the united states: a real-world evidence study using the rett syndrome natural history study database. Journal of Neurodevelopmental Disorders, Jul 2024. URL: https://doi.org/10.1186/s11689-024-09557-6, doi:10.1186/s11689-024-09557-6. This article has 8 citations and is from a peer-reviewed journal.
(NCT05898620 chunk 1): A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome. Neurogene Inc.. 2023. ClinicalTrials.gov Identifier: NCT05898620
(NCT06739434 chunk 1): GCB-002 in Treatment of Patients With Rett Syndrome. Genecombio Ltd.. 2024. ClinicalTrials.gov Identifier: NCT06739434
(NCT06856759 chunk 1): Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome. Guangzhou Women and Children's Medical Center. 2025. ClinicalTrials.gov Identifier: NCT06856759
(NCT05898620 chunk 2): A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome. Neurogene Inc.. 2023. ClinicalTrials.gov Identifier: NCT05898620

Ask OpenScientist

OpenScientist Report

Mappings

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Rett Syndrome — Comprehensive Disease Characteristics Research Report (Genetic)

Target Disease

Executive overview

1. Disease information

1.1 What is the disease?

1.2 Key identifiers

1.3 Synonyms / alternative names

1.4 Evidence provenance: individual vs aggregated

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

2.5 Genetic architecture details (hotspots)

3. Phenotypes

3.1 Core phenotype set and natural history (symptoms/signs)

3.2 Phenotype frequencies (from RNHS real-world cohort)

3.3 Quality of life impact

3.4 Suggested HPO terms (examples)

4. Genetic / molecular information

4.1 Causal genes

4.2 Inheritance

4.3 Pathogenic variants (high-level)

4.4 Modifier genes / epigenetics

5. Environmental information

6. Mechanism / pathophysiology

6.1 Current understanding (key concepts)

6.2 Recent developments (2023–2024): single-cell transcriptomics of progression

6.3 Suggested GO and CL terms (examples)

7. Anatomical structures affected

7.1 Organ/system level

7.2 Tissue/cell level

8. Temporal development

9. Inheritance and population

9.1 Epidemiology

9.2 Survival / prognosis (headline)

10. Diagnostics

10.1 Clinical criteria

10.2 Genetic testing

10.3 Biomarkers / imaging / electrophysiology

11. Outcome / prognosis

12. Treatment

12.1 Approved pharmacotherapy: trofinetide (2023)